|
Jul 25
|
Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development
|
|
Jul 25
|
2 Cash-Producing Stocks to Keep an Eye On and 1 We Find Risky
|
|
Jul 24
|
Roche Weighs Selling Drugs Directly to Patients in Bid to Lower U.S. Prices
|
|
Jul 24
|
Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?
|
|
Jul 24
|
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
|
|
Jul 24
|
Bausch Health Announces the Appointment of Two New Members to Its Board of Directors
|
|
Jul 24
|
ModelOp Transforms Enterprise AI Governance with Launch of the First Agentic AI Chat Interface and Controls for Agentic AI
|
|
Jul 24
|
How Bristol Myers Squibb uses AI to validate drugs before they’re even in the lab
|
|
Jul 24
|
Q1 Earnings Recap: Bristol-Myers Squibb (NYSE:BMY) Tops Branded Pharmaceuticals Stocks
|
|
Jul 23
|
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
|
|
Jul 23
|
Jim Cramer on Bristol-Myers: “Never Seen it This Cheap”
|
|
Jul 23
|
Will Keytruda Continue to Aid MRK's Top Line Ahead of Q2 Earnings?
|
|
Jul 23
|
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings
|
|
Jul 22
|
Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know
|
|
Jul 22
|
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
|
|
Jul 22
|
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
|
|
Jul 22
|
Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment
|
|
Jul 22
|
Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?
|
|
Jul 21
|
EdgeOne Medical Announces Appointment of Michael Denzer as VP, Client Relations to Further Elevate Product Innovation and Client Partnerships
|
|
Jul 21
|
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
|